Efficacy of anti-IL-5 therapy with mepolizumab for severe bronchial asthma and concomitant inflammatory nasal diseases in real clinical practice
- Authors: Naumova V.V.1, Beltyukov E.K.1, Kiseleva D.V.1
-
Affiliations:
- Ural State Medical University
- Issue: Vol 19, No 1 (2022)
- Pages: 67-79
- Section: Original studies
- URL: https://rusalljournal.ru/raj/article/view/1519
- DOI: https://doi.org/10.36691/RJA1519
- ID: 1519
Cite item
Abstract
BACKGROUND: T2 inflammation underlies nonallergic eosinophilic severe bronchial asthma and chronic rhinosinusitis with nasal polyposis. Existing targeted anti-IL-5 drugs can improve the clinical and functional parameters in patients with a combination of severe asthma and CRSwNP.
AIM: To evaluate mepolizumab efficacy in patients with nonallergic severe asthma and concomitant inflammatory nasal diseases in real clinical practice.
MATERIALS AND METHODS: The study was conducted without a control group, by comparing related populations (before–after analysis) and based on the Sverdlovsk regional register of adult patients with severe asthma and concomitant inflammatory nasal diseases. The primary endpoints were asthma control achievement (ACT questionnaire) and a decrease in the proportion of patients with uncontrolled severe asthma. The number of asthma exacerbations, emergency calls and hospitalizations, quality of life according to the AQLQ questionnaire, peripheral blood eosinophil level, and respiratory function (the volume of forced exhalation in the first second, the forced vital capacity of the lungs, as well as the ratio of these parameters) were also assessed. The dynamics of nasal symptoms was assessed using the SNOT-22 questionnaire and visual analog scale.
RESULTS: During 12 months of therapy with mepolizumab, the ACT score increased from 9 (Q1–Q3, 7–11) to 22 (Q1–Q3, 21–24) points (p <0.001). The proportion of patients with uncontrolled asthma decreased from 100% to 10% (p <0.001). The number of asthma exacerbations decreased from 3.18±2.8 per patient per year to 0 (p <0.001), and that of hospitalizations decreased from 0.57±0.9 per patient per year to 0 (p=0.007). The quality of life according to the AQLQ increased from 3.48±1.05 (95% CI, 2.73–4.24) to 5.59±0.88 points (95% CI, 4.96–6.22) (p <0.001). The number of blood eosinophils decreased from 442 (Q1–Q3, 336–853) to 90 (Q1–Q3, 73–117) cells/µL (p <0.001). There was increase in FEV1 from 63.9%±24.2% (95% CI, 46.6–81.2) to 80.5%±18.3% (95% CI, 67.4–93.6) (p=0.015). Decreases in the SNOT-22 questionnaire score by 33 points, from 45±30 to 22±15 (p=0.006), and in the visual analog scale score by 5 points, from 8 (Q1–Q3, 5–8) to 3 (Q1–Q3, 3–5) (p=0.017), were also noted.
CONCLUSIONS: Based on the study results, there were asthma control improvement, a decrease in asthma exacerbations, and quality of life improvement according to the AQLQ. A statistically significant decrease in the number of peripheral blood eosinophils and respiratory function improvement were also revealed. In patients with concomitant inflammatory nasal diseases, significant improvement in nasal breathing was noted, which was confirmed by the scores of the SNOT-22 questionnaire and visual analog scale.
Full Text

About the authors
Veronika V. Naumova
Ural State Medical University
Author for correspondence.
Email: nika.naumova@gmail.com
ORCID iD: 0000-0002-3028-2657
SPIN-code: 8210-6478
ResearcherId: AAI-1588-2020
MD, Cand. Sci. (Med.), assistant of the Department of Faculty Therapy, Endocrinology, Allergology and Immunology
Russian Federation, 3, Repina str., Ekaterinburg, 620028Evgeny K. Beltyukov
Ural State Medical University
Email: asthma@mail.ru
ORCID iD: 0000-0003-2485-2243
SPIN-code: 6987-1057
ResearcherId: AAI-1608-2020
MD, Dr. Sci. (Med.), Professor, Professor of the Department of Faculty Therapy, Endocrinology, Allergology and Immunology
Russian Federation, 3, Repina str., Ekaterinburg, 620028Darina V. Kiseleva
Ural State Medical University
Email: darinakiseljova@mail.ru
ORCID iD: 0000-0002-7847-5415
SPIN-code: 9446-7866
MD, Assistant of the Department of Faculty Therapy, Endocrinology, Allergology and Immunology
Russian Federation, 3, Repina str., Ekaterinburg, 620028References
- Global Initiative for Asthma. Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients. v. 2.0, April 2019. Available from: https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf. Accessed: 15.01.2022.
- Taillé C, Chanez P, Devouassoux G, et al. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: Results from a French early access programme. Eur Res J. 2020;55(6):1902345. doi: 10.1183/13993003.02345-2019
- Heffler E, Blasi F, Latorre M, et al. The Severe Asthma Network in Italy: findings and perspectives. J Allergy Clin Immunol Pract. 2019;7(5):1462–1468. doi: 10.1016/j.jaip.2018.10.016
- Harrison T, Canonica GW, Chupp G, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Res J. 2020;56(4):2000151. doi: 10.1183/13993003.00151-2020
- Trojan TD, Bird AJ. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Pediatrics. 2013;132(Suppl 1):S48–S48. doi: 10.1542/peds.2013-2294bbbb
- Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Res Med. 2017;5(5):390–400. doi: 10.1016/s2213-2600(17)30125-x
- Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England J Med. 2014;371(13):1198–1207. doi: 10.1056/NEJMoa1403290
- Harvey ES, Langton D, Katelaris C, et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Res J. 2020;55(5):1902420. doi: 10.1183/13993003.02420-2019
- Lemiere C, Taillé C, Lee JK, et al. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials. Respiratoty Research. 2021;22(1):184. doi: 10.1186/s12931-021-01767-z
- Detoraki A, Tremante E, D’Amato M, et al. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study. Therapeutic Adv Res Dis. 2021;15:175346662110093. doi: 10.1177/17534666211009398
- Numata T, Nakayama K, Utsumi H, et al. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis. BMC Pulmonary Med. 2019;19(1):176. doi: 10.1186/s12890-019-0952-1
- Crimi C, Campisi R, Cacopardo G, et al. Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities. World Allergy Org J. 2020;13(9):100462. doi: 10.1016/j.waojou.2020.100462
- Kurosawa M, Ogawa K, Sutoh E. Favorable clinical efficacy of mepolizumab on the upper and lower airways in severe eosinophilic asthma: A 48-week pilot study. Eur Annals Allergy Clin Immunol. 2019;51(5):213–221. doi: 10.23822/eurannaci.1764-1489.94
- Yilmaz İ, Türk M, Bahçecıoğlu S, et al. Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: Single center, real life study. Turkish J Med Sci. 2020;44(2):433–441. doi: 10.3906/sag-1912-62
- Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Res J. 2013;43(2):343–373. doi: 10.1183/09031936.00202013
- Global Initiative for Asthma. Global strategy for asthma management and prevention, updated 2018. Available from: https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-V1.3-002.pdf. Accessed: 15.01.2022.
- Beltyukov EK, Shelyakin VA, Naumova VV, et al. Organization of immunobiological therapy of severe bronchial asthma in the Sverdlovsk region. Russ Allergol J. 2021;18(1):6–17. (In Russ). doi: 10.36691/RJA1414an
- Buhl R., Humbert M., Bjermer L., et al. Expert group of the European Consensus Meeting for Severe Eosinophilic Asthma. Severe eosinophilic asthma: a roadmap to consensus. Eur Res J. 2017;49(5):1700634. doi: 10.1183/13993003.00634-2017
- Ilina NI, Kurbacheva OM, Pavlova KS, Polner SA. Federal clinical recommendations. Allergic rhinitis. Russ J Allergy. 2018;15(4):43–53. (In Russ). doi: 10.36691/rja135
- The Russian Association of Allergology and Clinical Immunology, National Medical Association of Otorhinolaryngologists, the Union of Pediatricians of Russia. Clinical recommendations. Allergic rhinitis. 2020. (In Russ). Available from: https://cr.minzdrav.gov.ru/clin_recomend. Accessed: 15.01.2022.
- Korn S, Both J, Jung M, et al. Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria. Ann Allergy Asthma Immunol. 2011;107(6):474–479.e2. doi: 10.1016/j.anai.2011.09.001
- Schleich F, Graff S, Nekoee H, et al. Real-word experience with mepolizumab: does it deliver what it has promised? Clin Exp Allergy. 2020;50(6):687–695. doi: 10.1111/cea.13601
- Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New England J Med. 2009;360(10):973–984. doi: 10.1056/NEJMoa0808991
- Chan R, Rui Wen Kuo C, Lipworth B. Disconnect between effects of mepolizumab on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2020;8(5):1714–1716. doi: 10.1016/j.jaip.2020.01.009
- Hopkins C, Gillett S, Slack R, et al. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009;34(5): 447–454. doi: 10.1111/j.1749-4486.2009.01995.x
Supplementary files
